In recent years, we have seen a surge in interest and investment in aging science, with over 300,000 articles published and 700 start-ups emerging, reflecting both the excitement and confusion surrounding this complex field.
Despite breakthroughs in understanding aging, Ramakrishnan cautions against the misleading claims of companies promoting untested longevity treatments, emphasizing the need for rigorous evidence before investing in such products.
While I appreciate the advancements in longevity research, my concern lies with the hype surrounding it, which often overshadows the real, evidence-based science that needs further exploration.
My aim in writing 'Why We Die' is to present a realistic perspective on aging and longevity, countering some of the exaggerated promises that permeate the market today.
Collection
[
|
...
]